--- title: "NexGel Receives Nasdaq Deficiency Notice Over Bid Price" type: "News" locale: "en" url: "https://longbridge.com/en/news/284059982.md" description: "NexGel, Inc. received a deficiency notice from Nasdaq due to its stock trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days to regain compliance or face potential delisting. NexGel may consider a reverse stock split to meet requirements. Currently, the stock is rated as a Buy with a $2.00 price target, but analysts express concerns over weak financial performance and risks associated with future financing and integration." datetime: "2026-04-24T22:33:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284059982.md) - [en](https://longbridge.com/en/news/284059982.md) - [zh-HK](https://longbridge.com/zh-HK/news/284059982.md) --- # NexGel Receives Nasdaq Deficiency Notice Over Bid Price ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from NexGel Inc ( (NXGL) ) is now available. On April 22, 2026, NexGel, Inc. disclosed that it received a deficiency notice from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, triggering noncompliance with Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading, and NexGel’s shares will continue to trade on the Nasdaq Capital Market under the symbol NXGL while the company evaluates its options. NexGel has 180 days, until October 19, 2026, to regain compliance by lifting its closing bid price to at least $1.00 for 10 consecutive business days, with the possibility of a second 180-day grace period if other listing criteria are met. The company said it may consider measures such as a reverse stock split to restore compliance, but warned that failure to meet the requirements could ultimately lead to delisting, with an option to appeal any such decision. The most recent analyst rating on (NXGL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page. **Spark’s Take on NXGL Stock** According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral. The score is constrained primarily by weak financial performance (ongoing losses, negative ROE, and persistent cash burn) and a technically weak price trend (below key moving averages with negative MACD). Offsetting these, the latest earnings call provided relatively strong forward-looking catalysts and profitability targets tied to the Celularity transaction, though financing/dilution and integration risks remain significant. To see Spark’s full report on NXGL stock, click here. **More about NexGel Inc** NexGel, Inc. is a publicly traded company listed on the Nasdaq Capital Market under the ticker symbol NXGL. The company’s stock is subject to Nasdaq’s continued listing standards, including minimum bid price and market value requirements that govern its eligibility to remain on the exchange. **Average Trading Volume:** 352,335 **Technical Sentiment Signal:** Sell **Current Market Cap:** $6.76M For a thorough assessment of NXGL stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [CELU.US](https://longbridge.com/en/quote/CELU.US.md) - [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md) - [CELUW.US](https://longbridge.com/en/quote/CELUW.US.md) ## Related News & Research - [Are Wall Street Analysts Bullish on Akamai Technologies Stock?](https://longbridge.com/en/news/286949319.md) - [Do Wall Street Analysts Like PTC Inc. Stock?](https://longbridge.com/en/news/286906040.md) - [03:00 ETGreenberg Traurig's Capital Markets Practice Recognized Across Five Winning Deals of the Year at Islamic Finance News Awards 2025](https://longbridge.com/en/news/287020144.md) - [Kornit Digital joins Craig-Hallum institutional investor conference, hosts one-on-one meetings](https://longbridge.com/en/news/287060555.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)